Population health & analytics · Post-acute care coordination
Olio
Olio is a care-coordination platform that connects hospitals, payers, and post-acute providers around transitions of care and shared workflows. It is not an FQHC quality-reporting suite or OR capacity tool.
Strong fit
- Health systems and payers that need shared care-coordination workflows across hospitals and post-acute partners
- Teams that will measure readmissions, length of stay, and network leakage after go-live
- Buyers comparing post-acute collaboration tools rather than enterprise risk-stratification suites
Weak fit
- FQHCs that only need UDS quality dashboards
- Buyers seeking OR capacity optimization
- Organizations with no post-acute network to coordinate
Bottom line
Olio earns a Recommend for health systems and payers whose bottleneck is care coordination across post-acute partners rather than another risk pyramid dashboard. Outcomes look strongest when discharge partners actually work inside the shared workflow and readmission metrics move. Product depth sits next to Trella on post-acute intelligence themes, more workflow/collaboration than Azara's FQHC analytics. Implementation is a network and workflow program. Pricing is custom. Third-party revenue estimates sit roughly $10-15M. Score sits with Elligint and above Relevant on our population-health board for post-acute coordination buyers.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Olio provides care-coordination software that connects hospitals, payers, and post-acute providers around transitions of care and shared workflows.
Compare Trella when the job is post-acute market intelligence, and Azara or Relevant when the buyer is an FQHC analytics team rather than a hospital-to-SNF coordination program.
Score reflects solid post-acute coordination marks on our population-health board.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Olio | 6.9 | 6.7 |
| Trella Health | 7.3 | 7.0 |
| Syra Health | 7.4 | 7.1 |
| Azara Healthcare | 7.6 | 7.2 |
| Persivia | 7.4 | 7.1 |
| Relevant Healthcare | 6.8 | 6.6 |
| Lightbeam Health Solutions | 6.8 | 6.5 |
| Elligint Health | 6.9 | 6.6 |
Pricing
| Item | Detail |
|---|---|
| Model | Custom SaaS for care-coordination across acute and post-acute networks. |
| What usually drives cost | Facilities in network, users, modules, and implementation services. |
| What to ask in diligence | Annual cost for your hospital and post-acute footprint, and how partner seats are licensed. |
| Published pricing | Public list price: not published. Expect a mid-market care-coordination quote. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Olio to function | |
| Named population-health or quality owner with authority over care-gap work | Dashboards without owners become wallpaper. |
| Clean attributed-lives or panel definition agreed with finance | Vague denominators erase savings claims. |
| EHR, claims, and ADT feed inventory documented | Missing feeds recreate blind spots. |
| Care-manager or partner capacity to act on lists | Unworked lists are not outcomes. |
| Contract metrics chosen before kickoff | Moving goalposts erase the engagement. |
| What will maximize your value | |
| Track gap closure, readmissions, or utilization weekly for 90 days | Login counts are not outcomes. |
| Start with one population or partner network first | Narrow wins beat empty enterprise banners. |
| Retire duplicate spreadsheet lists after parallel month | Dual entry doubles cost. |
| Review unworked high-risk or transition patients in a standing huddle | Silent queues hide failure. |
| Publish a quarterly outcomes digest to clinical leaders | Hidden backlogs surprise board reviews. |
| Deal-breakers | |
| You have no value-based, quality, or post-acute program to act on. | |
| Nobody will own follow-up work. | |
| You refuse any EHR or claims data sharing. | |
| You expect an EHR replacement from a population-health layer. | |
| Leadership will not measure outcomes. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Scope & data | 4–8 weeks — Lives, feeds, success metrics. |
| 2 | Integrate | 2–4 months — Claims/EHR/ADT; validation. |
| 3 | Pilot | 1–2 months — One contract, site, or partner cohort. |
| 4 | Expand | Ongoing — More lives; care-ops tuning. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.